Oxford Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Oxford Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,516	Closed	-$84K	–	251
2019 Q4	$84K	Buy	+14,516	New	+$83.8K	﹤0.01%	1631
2019 Q3	–	Sell	-17,722	Closed	-$106K	–	1688
2019 Q2	$106K	Sell	17,722 -26,807	-60%	-$202K	﹤0.01%	1607
2019 Q1	$402K	Sell	44,529 -14,434	-24%	-$123K	0.01%	1305
2018 Q4	$489K	Sell	58,963 -16,483	-22%	-$169K	0.01%	1205
2018 Q3	$1.03M	Buy	75,446 +49,791	+194%	+$404K	0.02%	999
2018 Q2	$207K	Buy	+25,655	New	+$205K	﹤0.01%	1584
2018 Q1	–	Sell	-14,287	Closed	-$95K	–	1579
2017 Q4	$95K	Buy	+14,287	New	+$94.1K	﹤0.01%	1525

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Oxford Asset Management's ALDX Position: Q1 2020 in Review

Oxford Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2020, closing a stake of 14,516 shares — an estimated $84K sold.

Oxford Asset Management first reported a position in ALDX in Q4 2017 and held it in 7 quarters. The position peaked at $1.03M in Q3 2018. 72 funds tracked by Wall St. Rank hold ALDX as of Q1 2020.

Oxford Asset Management reported no remaining Aldeyra Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 14,516 Aldeyra Therapeutics shares in Q1 2020, an estimated $84K.
Oxford Asset Management first reported a position in Aldeyra Therapeutics in Q4 2017 and held it in 7 quarters.
Oxford Asset Management's Aldeyra Therapeutics position peaked at $1.03M in Q3 2018.
72 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.